Microplastics and Nanoplastics as Emerging Contributors to Cardiovascular Disease: Mechanisms, Clinical Evidence, and Therapeutic Opportunities

Abstract

Microplastics and nanoplastics (MNPs) are increasingly recognized as environmental contaminants with potential cardiovascular relevance. Recent studies have identified MNPs in human blood, arterial tissue, and atherosclerotic plaques, raising concern that chronic exposure may contribute to vascular injury and disease progression. Clinical evidence has reported associations between MNP-positive atherosclerotic plaques and higher observed rates of major adverse cardiovascular events. Building on research concepts initiated in April 2024 (with subsequent proposal activity in May 2024 and July 2024), this perspective reviews key mechanistic and human data relevant to cardiovascular risk. Nanoplastics are not simply smaller microplastics; their greater accessible surface area and higher interactive density may amplify biological reactivity in vascular systems. Interaction-mediated mitigation strategies that promote aggregation or sequestration without polymer degradation are proposed as biologically plausible complements to exposure reduction. Targeted lipid nanoparticle (LNP) delivery of anti-inflammatory and antioxidant compounds may represent a future therapeutic avenue for at-risk populations.

Note: The concepts discussed here are consistent with earlier solo inventor-generated filings and proposal materials from 2024, which broadly contemplated therapeutic and diagnostic approaches for plastic-associated human disease, including cardiovascular and inflammatory contexts.

This paper is also available at: https://doi.org/10.5281/zenodo.19753798

Figure 1. Early Therapeutic Concept for Microplastic-Associated Cardiovascular Pathology (2024). Adapted from author-generated proposal materials prepared in July 2024. The schematic illustrates targeted intervention concepts for microplastic burden or related inflammatory cardiovascular pathology, including macrophage-focused delivery strategies within atherosclerotic lesions. Included to document continuity of concept development and translational rationale.

1. Introduction

Cardiovascular disease remains the leading cause of death worldwide. While traditional risk factors such as hypertension, dyslipidemia, diabetes, smoking, and obesity are well established, environmental contributors continue to emerge as important modifiers of risk.

Among these, microplastics and nanoplastics have received increasing attention because of their widespread presence in food, water, air, and human tissues. Detection of MNPs in circulating blood, arterial tissue, and atherosclerotic plaques raises the possibility that chronic particulate exposure may exacerbate vascular pathology.

This paper summarizes current evidence and outlines a translational framework for future mitigation strategies.

2. Clinical and Human Evidence

Several human studies have reported direct detection of MNPs in cardiovascular-relevant tissues.

A 2024 study published in the New England Journal of Medicine reported microplastics and nanoplastics within human carotid atherosclerotic plaques. Individuals with MNP-positive plaques had higher observed rates of myocardial infarction, stroke, or death during follow-up compared with those without detectable particles.

Additional studies have reported elevated levels of polymers such as polyethylene terephthalate (PET) and related materials in diseased arterial tissue relative to control samples.

While causality has not been established, these findings support continued investigation into MNP burden as a potential modifier of cardiovascular outcomes.

3. Mechanistic Pathways Potentially Relevant to Cardiovascular Disease

Multiple biological pathways may connect MNP exposure to cardiovascular pathology.

3.1 Endothelial Dysfunction

The vascular endothelium regulates tone, permeability, thrombosis, and inflammation. Experimental studies suggest particulate exposure may impair nitric oxide signaling, increase oxidative stress, and disrupt endothelial homeostasis.

3.2 Chronic Vascular Inflammation

Persistent particulate burden may activate inflammatory signaling pathways including NF-κB, IL-6, TNF-α, and related cytokine networks, contributing to plaque progression and vascular dysfunction.

3.3 Oxidative Stress and Mitochondrial Injury

MNP exposure has been associated in experimental systems with reactive oxygen species generation, mitochondrial dysfunction, and redox imbalance, all of which are relevant to vascular aging and atherosclerosis.

3.4 Foam Cell Formation and Plaque Instability

Macrophage uptake of lipids and inflammatory stimuli drives foam cell formation in atherosclerosis. MNP interactions with macrophages and lipid-rich environments may influence plaque biology and stability.

3.5 Thrombotic and Hemostatic Effects

Emerging work suggests particulate exposure may alter platelet activation, coagulation pathways, or endothelial injury responses, warranting further investigation into thrombotic risk.

4. Why Nanoplastics May Matter Disproportionately

Nanoplastics should not be viewed merely as smaller versions of microplastics. Their reduced size may permit broader biodistribution, deeper tissue penetration, and more frequent interaction with cells, proteins, and vascular surfaces.

In addition, smaller particles may present greater accessible surface area and higher interactive density relative to mass, potentially amplifying biologically relevant interfaces. Even at low concentrations, these properties may make nanoplastics particularly important in cardiovascular systems.

5. Therapeutic and Preventive Opportunities

Source reduction, cleaner materials, filtration, and exposure avoidance remain foundational strategies. However, complementary biological approaches may also emerge.

5.1 Interaction-Mediated Mitigation

Rather than relying solely on polymer degradation, interaction-mediated strategies aim to cluster, sequester, or neutralize particulate burden.

Potential benefits may include:

• reduced reactive surface area

• decreased vascular interface activity

• improved clearance potential of larger aggregates

• lower inflammatory signaling

5.2 Targeted Delivery of Protective Compounds

Advanced carrier systems such as lipid nanoparticles may enable vascular-targeted delivery of compounds with anti-inflammatory, antioxidant, endothelial-protective, or plaque-stabilizing properties.

Illustrative candidate classes may include:

• polyphenols

• flavonoids

• mitochondrial support compounds

• enzymes

• anti-inflammatory biologics

• other AI-prioritized agents

5.3 Precision Biomonitoring

Future clinical frameworks may integrate blood or urine monitoring with adaptive intervention strategies for high-risk populations.

6. Research Priorities

Important next steps include:

• standardized methods for measuring MNPs in cardiovascular tissues and biofluids

• longitudinal cohort studies with exposure metrics

• mechanistic vascular and thrombosis models

• plaque biology studies

• therapeutic proof-of-concept experiments

• biomonitoring-guided prevention strategies

Conclusion

Microplastics and nanoplastics may represent a modifiable environmental contributor to cardiovascular disease through mechanisms involving endothelial dysfunction, inflammation, oxidative stress, plaque instability, and thrombosis. Although definitive causality in humans remains to be established, current evidence supports urgent investigation into their cardiovascular relevance. Integrating exposure science with translational mitigation strategies may help protect vascular health in an increasingly plastic-contaminated world.

Keywords

microplastics; nanoplastics; cardiovascular disease; atherosclerosis; endothelial dysfunction; vascular inflammation; thrombosis; environmental health; biomonitoring; therapeutics

Representative References

• Marfella R, et al. Microplastics and Nanoplastics in Human Atherosclerotic Plaques. N Engl J Med. 2024.

• Yang Y, et al. Microplastics in human blood and cardiovascular tissue. Environ Int. 2023.

• Li Z, et al. Inhaled microplastics exacerbate atherosclerosis in mouse models. J Hazard Mater. 2024.

• Wang et al. Polyethylene terephthalate microplastics in human arterial tissues. Environ Pollut. 2023.

• Hou B, et al. Chronic particulate exposure and cardiovascular inflammation. Sci Total Environ. 2024.

• Zhao Q, et al. Nanoplastics cross biological barriers and accumulate in vascular tissue. Environ Int. 2023.

• Ding Y, et al. Nanoplastics induce oxidative stress and mitochondrial dysfunction in endothelial cells. Environ Sci Technol. 2023.

• Park JH, et al. Polystyrene microplastics promote foam cell formation. Environ Pollut. 2023.